Talk:Oklahoma Medical Research Foundation/Archive 1

Archive 1

Revised section: Education programs

In 1956, OMRF established its Sir Alexander Fleming Scholar Program, a summer research training program for Oklahoma high school and college students. Since then, more than 400 students have been named Fleming Scholars.

OMRF’s Foundation Scholar Program provides Oklahoma’s high school science teachers with novel tools and instructional techniques to take back to their classrooms. Founded in 1988, the program offers 4 weeks of experience working in the foundation laboratories.

The 'Teen Leaders in Philanthropy' class was created in 2012 to let up to 40 high school sophomores, juniors and seniors develop hands-on leadership skills and an understanding of what a nonprofit organization does. The program gives participants a chance to learn from a variety of charitable organizations, donors and volunteers during nine sessions throughout the school year.

OMRF also provides the training ground for four graduate and postdoctoral students each year in the M.D./Ph.D Program at the University of Oklahoma Medical School. 

---

end new section----------

DeknMike (talk) 02:22, 26 February 2019 (UTC)

Revised slightly (kept all refs) and used to replace what was the existing Education programs section. David notMD (talk) 13:55, 1 April 2019 (UTC)

Request edit on 24 May 2019

Extended content

New Lede The Oklahoma Medical Research Foundation (OMRF), located in Oklahoma City, Oklahoma, is an independent, nonprofit biomedical research institute, founded with the mission of helping Oklahomans and people everywhere live longer, healthier lives. It is funded by a mix of public donations and competitive grants. Established in 1946 by 30 business leaders from around the state, is one of the oldest independent medical research institutions in the country. It sits adjacent to the campus of the University of Oklahoma Medical School, and near 3 hospitals. OMRF is a member of the Association of Independent Research Institutes. Using a cross-disciplinary approach to medical research, OMRF’s scientists have accumulated more than 700 U.S. and international patents and have spun off 11 biotech companies. The institute is one of the few in the country funded not by a flagship donor, but instead by a wide array of sponsors, including research grants from a variety of sources. Independent rating service Charity Navigator notes 91.1% of the charity's $75 Million of expenses are for the programs and services it delivers and only 6.1% on administrative expenses. Charity Navigator has a rating score that assesses financial health, accountability and transparency. For 2017, they assessed OMRF as Category 4 of 4 (the highest) with a score of 93.94, the highest among similar institutions. OMRF receives more than $30 million annually in competitive research grants from the National Institutes of Health and other granting agencies. It has about 500 employees, including 135 individuals with medical degrees or doctorates, coming from 29 countries. Approximately 10% of the staff are junior scientists who have recently completed their doctoral degrees -- known as ‘post-doctoral students’ or ‘post-docs’ – who spend 3 to 5 years at a research institution. The current president of OMRF is Stephen M. Prescott. ------------------end of new Lede--------------- DeknMike (talk) 03:04, 24 May 2019 (UTC) Revised: Areas of Research OMRF has noted expertise in the study of the human immune system. OMRF uses a cross-disciplinary approach to medical research that has helped its scientists generate more than 700 U.S. and international patents. OMRF scientists study how the human immune system forms—or fails to form—immune responses. Their focus is on understanding the nature of disease to create and test effective treatments. The top areas of study are heart disease, Cancer, Diabetes, Alzheimer’s disease, and immune-response diseases such as Lupus, Sjögren's syndrome, Multiple Sclerosis and Arthritis Discoveries at OMRF led to Xigris, the first FDA-approved drug for the treatment of severe sepsis, and Ceprotin, a therapy for people suffering from a rare and life-threatening blood disorder known as protein C deficiency. Research at OMRF also identified the enzyme believed responsible for Alzheimer’s disease and laid the groundwork for OncoVue, a breast cancer risk assessment test. Alzheimer’s and brain diseases OMRF’s free radical biology and aging research program focuss on the mechanisms that cause neurodegenerative diseases such as Alzheimer’s, Parkinson's disease, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease). In 2007, OMRF scientists, led by Dr Jordan J.N. Tang, were able to map a blueprint of the Alzheimer's. Tang uncovered a molecular mechanism that links an Alzheimer’s susceptibility gene (known as E4) to the process of disease onset. Dr Tang's team was able to map a blueprint of the Alzheimer's, and treatments for HIV/AIDS and for hypertension. Although Dr Tang has since retired, his research has been recognized and honored by the Guggenheim Foundation, National Institutes, Chinese Academy of Sciences and the United Nations. He is the only Oklahoman ever to receive the Alzheimer’s Association of America’s highest research prize: the $1 million Pioneer Award. Cancer and Immunobiology Technology developed in the laboratories of Eldon Jupe and Linda F. Thompson led to the creation of a test for assessing breast cancer risk in women. Marketed as OncoVue, the test is produced by Intergenetics, Inc. and available in clinics the U.S. Paul W. Kincade leads a group of immunologists in the study of the causes of lymphomas, leukemias and myelomas. With a research-grade magnetic resonance imaging facility, OMRF scientists are developing methods of using MRI to speed the process of identifying and treating brain, liver and bladder cancers. In 2006, molecular biologist Gary J. Gorbsky and his lab were the first to reverse the process of cell division, a discovery detailed in the journal Nature that may have implications for the prevention and treatment of cancer and birth defects. Gary J Gorbsky is Chair of the Program in Cell Cycle and Cancer Biology. Heart and blood diseases Led by Rodger P. McEver and Charles T. Esmon OMRF’s cardiovascular biology research program works to pinpoint the origins of cardiovascular disease. The nature of research is that the knowledge can be used in a variety of ways. One example is Dr Esmon’s research into recombinant human activated protein C (rhAPC). It was used as the core understanding for two different drugs, treating two different medical conditions, with differing results. CEPROTIN was developed for patients (usually children) with life-threatening blood-clotting complications related to severe congenital Protein C deficiency. Xigris is an Activated protein C (APC) for treatment in sepsis (blood poisoning) that was approved in Novermber 2001. CEPROTIN was approved in 2007 . While CEPROTIN continues to be a significant therapy for those with Protein C deficiency, the story of Xigris shows that not all treatments work the same for all people, and that research must be continuous. Eli Lilly created Xigris to treat sepsis, and early trials seemed to show it worked, but subsequent studies were terminated prematurely because of lack of efficacy After multiple studies, the root cause was when the patient was at risk for extended bleeding, because rhAPC has anticoagulant properties. The deep research in labs such as OMRF’s cardiovascular biology helps discover both treatments and when to use them. Dr McEver also discovered the SelG1 antibody, which works to reduce pain for those afflicted with sickle cell disease, a lifelong hereditary blood disorder that causes debilitating pain, organ damage and premature death. Lupus and autoimmune diseases OMRF’s largest research program is dedicated to the study and treatment of systemic lupus erythematosus and other autoimmune diseases. Led by physician-researchers Judith A. James, Robert Scofield and Morris Reichlin, this group has identified antibodies that appear in the blood years before the clinical onset of lupus. They also are studying the role a common virus may play in triggering lupus. Their work led the National Institutes of Health to establish the Lupus Family Registry and Repository at OMRF. The LFRR is a resource that scientists worldwide can use in their own lupus research. The collection includes DNA, sera, plasma, and data from systemic lupus patients, first degree relatives, and healthy volunteers. Study participation involves completing paperwork and donating a one-time blood sample. ---------------end of rewritten Areas of Research---------------- References

DeknMike (talk) 03:04, 24 May 2019 (UTC)

@DeknMike: I've moved your {{request edit}} to this talk page from Template talk:COI editnotice. Someone will look this over soon. – Þjarkur (talk) 19:03, 24 May 2019 (UTC)

Reply 25-MAY-2019

  Edit request declined  

• Portions of text in your proposal are insufficiently paraphrased from their source materials. All additions to an article need to be written using an editor's own words and phrasing.
• Kindly rewrite your proposal along these lines and feel free to submit that proposal in a new edit request at your earliest convenience.

Regards,  Spintendo  02:30, 26 May 2019 (UTC)

Replacement for Research Section

Explanation of issue: The research section contains names of individuals no longer working at OMRF, and projects that have aged. The replacement text updates the areas of research and adds references beyond Foundation sources. DeknMike (talk) 02:49, 20 July 2019 (UTC)

---

Extended content

The motto of the Foundation is "That More May Live Longer." The early research was focused on understanding the nature of what made a person healthy, and understanding what happens when immunity malfunctions. OMRF scientists continue to study how the human immune system forms — or fails to form — immune responses, and to create and test effective treatments. At one time, the Foundation operated a research hospital, where patients would come for ongoing study and experimental treatments. The 14-room hospital opened in July, 1951 and the first patient was Lillian Sims. Other patients allowed researchers to study the effects of idleness and of nutrition. Many children came as a last-ditch hope in their waning days of serious illness. The hospital closed in 1976 and now only does out-patient study and consults to nearby hospitals. OMRF uses a cross-disciplinary approach to medical research that has helped its scientists generate more than 700 U.S. and international patents. The top areas of study are heart disease, Cancer, Diabetes, Alzheimer’s disease, and immune-response diseases such as Lupus, Sjögren's syndrome, Multiple Sclerosis and Arthritis Alzheimer’s and brain diseases In 2000, OMRF scientists created an inhibitor that, in vitro, stopped the enzyme thought to cause Alzheimer's disease. The biotechnology company CoMentis has since built on that discovery to create an experimental drug for the treatment of Alzheimer’s. In 2007, they uncovered a molecular mechanism that links an Alzheimer’s susceptibility gene (known as E4) to the process of disease onset. OMRF’s scientists continue to focus on the mechanisms that cause neurodegenerative diseases such as Parkinson's Parkinson's disease, Huntington's Huntington's disease and ALS (Lou Gehrig’s disease) Amyotrophic Lateral Sclerosis. Cancer and Immunobiology Technology developed in the laboratories led to the creation of a test for assessing breast cancer risk in women. Marketed as OncoVue, the test is produced by Intergenetics, Inc. and available in clinics the U.S. With a research-grade magnetic resonance imaging facility, OMRF scientists are developing methods of using MRI to speed the process of identifying and treating brain, liver and bladder cancers. In 2006, OMRF scientists were the first to reverse the process of cell division, a discovery detailed in the journal Nature that may have implications for the prevention and treatment of cancer and birth defects. Heart and blood diseases OMRF research into recombinant human activated protein C (rhAPC) was used as the core understanding for two different drugs, treating two different medical conditions, with differing results. CEPROTIN was developed for patients (usually children) with life-threatening blood-clotting complications related to severe congenital Protein C deficiency. Xigris is an Activated protein C (APC) for treatment in sepsis (blood poisoning) that was approved in Novermber 2001. CEPROTIN was approved in 2007 . While CEPROTIN continues to be a significant therapy for those with Protein C deficiency, the story of Xigris shows that not all treatments work the same for all people, and that research must be continuous. Eli Lilly created Xigris to treat sepsis, and early trials seemed to show it worked, but subsequent studies were terminated prematurely because of lack of efficacy After multiple studies, the root cause was when the patient was at risk for extended bleeding, because rhAPC has anticoagulant properties. The deep research in labs such as OMRF’s cardiovascular biology helps discover both treatments and when to use them. Lupus and autoimmune diseases OMRF’s largest research program is dedicated to the study and treatment of systemic lupus erythematosus and other autoimmune diseases. This group has identified antibodies that appear in the blood years before the clinical onset of lupus. They also are studying the role a common virus may play in triggering lupus. References

DeknMike (talk) 02:49, 20 July 2019 (UTC)

Reply 19-JUL-2019

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request.  Spintendo  03:59, 20 July 2019 (UTC)

Proposal review 19-JUL-2019

The motto of the Foundation is "That More May Live Longer." The early research was focused on understanding the nature of what made a person healthy, and understanding what happens when immunity malfunctions.  Declined. OMRF scientists continue to study how the human immune system forms — or fails to form — immune responses, and to create and test effective treatments.  Declined. At one time, the Foundation operated a research hospital, where patients would come for ongoing study and experimental treatments. The 14-room hospital opened in July, 1951 and the first patient was Lillian Sims. Other patients allowed researchers to study the effects of idleness and of nutrition. Many children came as a last-ditch hope in their waning days of serious illness. The hospital closed in 1976 and now only does out-patient study and consults to nearby hospitals.  Declined. OMRF uses a cross-disciplinary approach to medical research that has helped its scientists generate more than 700 U.S. and international patents Clarification needed. In 2000, OMRF scientists created an inhibitor that, in vitro, stopped the enzyme thought to cause Alzheimer's disease. The biotechnology company CoMentis has since built on that discovery to create an experimental drug for the treatment of Alzheimer’s. In 2007, they uncovered a molecular mechanism that links an Alzheimer’s susceptibility gene (known as E4) to the process of disease onset. OMRF’s scientists continue to focus on the mechanisms that cause neurodegenerative diseases such as Parkinson's Parkinson's disease, Huntington's Huntington's disease and ALS (Lou Gehrig’s disease) Amyotrophic Lateral Sclerosis.  Declined. Technology developed in the laboratories led to the creation of a test for assessing breast cancer risk in women. Marketed as OncoVue, the test is produced by Intergenetics, Inc. and available in clinics the [sic] U.S.  Unable to review. With a research-grade magnetic resonance imaging facility, OMRF scientists are developing methods of using MRI to speed the process of identifying and treating brain, liver and bladder cancers.  Declined. In 2006, OMRF scientists were the first to reverse the process of cell division, a discovery detailed in the journal Nature  Approved. that may have implications for the prevention and treatment of cancer and birth defects.  Declined. OMRF research into recombinant human activated protein C (rhAPC) was used as the core understanding for two different drugs, treating two different medical conditions, with differing results. CEPROTIN was developed for patients (usually children) with life-threatening blood-clotting complications related to severe congenital Protein C deficiency. Xigris is an Activated protein C (APC) for treatment in sepsis (blood poisoning) that was approved in Novermber 2001. CEPROTIN was approved in 2007.  Declined. While CEPROTIN continues to be a significant therapy for those with Protein C deficiency, the story of Xigris shows that not all treatments work the same for all people, and that research must be continuous.  Declined. Eli Lilly created Xigris to treat sepsis, and early trials seemed to show it worked, but subsequent studies were terminated prematurely because of lack of efficacy. After multiple studies, the root cause was when the patient was at risk for extended bleeding, because rhAPC has anticoagulant properties.  Declined. OMRF’s largest research program is dedicated to the study and treatment of systemic lupus erythematosus and other autoimmune diseases. This group has identified antibodies that appear in the blood years before the clinical onset of lupus.  Declined. They also are studying the role a common virus may play in triggering lupus. Clarification needed. ___________

Request edit - Education section

OMRF has discontinued the Foundation Scholar Program. Please remove that paragraph. The rest of the section remains valid.DeknMike (talk) 03:15, 20 July 2019 (UTC)

Reply 19-JUL-2019

  Edit request implemented  

• Information on the Foundation Scholar Program was omitted.

Regards,  Spintendo  04:10, 20 July 2019 (UTC)

Request edit

Rather than the one instance of grants, request a new section titled Donors & Funding with text as follows. DeknMike (talk) 03:22, 20 July 2019 (UTC)

---

Extended content

OMRF is funded primarily through grants and independent contributions. Two-thirds (65.3%) comes from government grants, and most of the rest comes from contributions and grants from other sources. A substantial part of the non-government contributions come from sources across Oklahoma, in small towns and the main cities, continually reinforcing OMRF’s role as Oklahoma’s medical research foundation. Independent rating service Charity Navigator notes 91.1% of the charity's $75 Million of expenses are for the programs and services it delivers and only 6.1% on administrative expenses. Charity Navigator has a rating score that assesses financial health, accountability and transparency; for 2017, they assessed OMRF as Category 4 of 4 (the highest) with a score of 93.94. Early Funding As an independent foundation not attached to a parent hospital or significant bequest, the Foundation struggled in its early years to create sufficient funding to hire top talent. Formal research started in 1953, and ongoing operations during the 1950s involved unique and varied fundraising approaches. For example, the Oklahoma State Coaches' Association took collections during halftime at sporting events; the first four years netted OMRF more than $56,000, mostly in coins. Many people still remember buckets being passed at OU and OSU football games. A number of community-based initiatives were created, including farmers dedicating acreage of their crops as an annual pledge, and mass-marketing solicitation for memorial gifts. The foundation has received gifts of cars, houses, and jars of change. When times were lean, staff members would occasionally take to the streets of Oklahoma City to solicit donations from passers by. However, most of the early funding came from the many oil and gas companies creating overnight fortunes, most often from the family matriarch. The sometimes extreme generosity and frequent challenges among company owners in the early years provided much-needed operating funds and most of the money to build the first Foundation buildings. All but the first of its seven buildings came from major gifts to the Foundation. Unusual Donations The Oklahoma Association of Mothers' Campaign started its long-standing support of OMRF in 1953. Women throughout Oklahoma raised funds to provide the foundation with equipment such as a respiratory gas analyzer, inverted microscopes, an oxygen unit, fraction collector and even television sets for hospital patients' rooms. Wheat Donations. In 1961, hundreds of Oklahoma wheat producers decided to donate a portion of their crops to OMRF. More than 450 farm families participated in the program, which donated in excess of 9,000 bushels of wheat to OMRF its first year. In 1962, farmers were mailed checks for $3.25, which was then the cost of enough seed to plant one acre of wheat. That acre was dedicated to OMRF. The foundation had wheat pledged as donations through the 1970s. Sr. Carl Bailey of Stroud donated a second hospital to OMRF. Guymon veterinarian W.F. Dunaway and his wife, Mada Louise, named OMRF the beneficiary of a significant charitable remainder trust, and the current OMRF clinic bears their names. The estate of an Alva farmer and rancher, Ed Massman, built the Massman Cancer Research Building. The estate of Rose Woodworth of Ardmore built OMRF's Acree-Woodworth Research Building. In 1931, Lynn Riggs published a play he called “Green Grow the Lilacs” which Rogers and Hammerstein adapted as the musical Oklahoma! When he died, he willed his 1% royalty to his 4 siblings. When his brother William Edgar Riggs died, OMRF received rights to that one-quarter share. As of the end of 2018, it has generated over $700,000 in earnings. References

— Preceding unsigned comment added by DeknMike (talk • contribs) 03:23, 20 July 2019 (UTC)

Reply 19-JUL-2019

  Edit request declined  

• Portions of the proposed text are insufficiently paraphrased from the source material.

Regards,  Spintendo  04:06, 20 July 2019 (UTC)

Archive 1